Sarah Krepp Sells 276 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) insider Sarah Krepp sold 276 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $60.87, for a total value of $16,800.12. Following the completion of the transaction, the insider owned 146,743 shares in the company, valued at approximately $8,932,246.41. This trade represents a 0.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Sarah Krepp also recently made the following trade(s):

• On Monday, April 13th, Sarah Krepp sold 4,557 shares of Liquidia stock. The shares were sold at an average price of $38.37, for a total value of $174,852.09.

Liquidia Price Performance

NASDAQ:LQDA opened at $62.32 on Friday. Liquidia Corporation has a one year low of $11.85 and a one year high of $66.24. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.03 and a current ratio of 2.22. The stock has a market cap of $5.54 billion, a PE ratio of 445.20 and a beta of 0.58. The stock has a 50 day moving average price of $46.27 and a 200 day moving average price of $39.40.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.11. The company had revenue of $132.87 million during the quarter, compared to analysts’ expectations of $119.44 million. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The company’s revenue for the quarter was up 4187.1% on a year-over-year basis. Equities research analysts expect that Liquidia Corporation will post 2.97 EPS for the current fiscal year.

Institutional Trading of Liquidia

Institutional investors have recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. purchased a new stake in Liquidia during the 4th quarter worth about $25,000. NewEdge Advisors LLC acquired a new position in Liquidia during the 2nd quarter worth approximately $25,000. Skandinaviska Enskilda Banken AB publ purchased a new stake in shares of Liquidia during the 3rd quarter worth approximately $30,000. FNY Investment Advisers LLC purchased a new stake in shares of Liquidia during the 3rd quarter worth approximately $34,000. Finally, Covestor Ltd lifted its stake in Liquidia by 41.9% in the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after buying an additional 359 shares in the last quarter. 64.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Raymond James Financial reiterated a “strong-buy” rating and issued a $68.00 target price on shares of Liquidia in a report on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a report on Tuesday, April 21st. Wall Street Zen upgraded Liquidia from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 16th. Needham & Company LLC lifted their target price on Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a report on Monday, May 11th. Finally, Wells Fargo & Company lifted their target price on Liquidia from $51.00 to $62.00 and gave the company an “overweight” rating in a report on Tuesday, May 12th. Three analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $53.50.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).